Daiichi Sankyo Company, Limited

Ricoh Company, Ltd.

Exelixis, Inc.

Kazumasa Aoki

Yasuyuki Ogawa

Osamu Iwamoto

Katsuyoshi Nakajima

Keiji Saito

Shinji Tanaka

Toru Taniguchi

Satoshi Shibuya

Susumu Iguchi

Kaori Ito

Nobuya Kurikawa

Hideji Miyanishi

Eriko Kioi

Natsumi Nishihama

Momoko Ogitani

Wataru Saitoh

Kenji Motohashi

Tsuyoshi Mikkaichi

Yoshimi Ohno

Daisuke Hata

Takayuki Hatase

Hiroyuki Tsuruoka

Shimpei Hirano

Kentoku Gotanda

Tomio Kimura

Noriyuki Hayashi

Toshio Kaneko

Kikuo Kazama

Yusuke Asoh

Koji Suda

Toshinobu Shoji

Raju Mohan

Matthew A Williams

John M Nuss

Richard Martin

Tie-Lin Wang

Hidenori Takahashi

Yoshiharu Hiruma

Akira Nakao

Takao Yamaguchi

Osamu Kanno

Mikio Kato

Ryoichi Tanaka

Hiroko Kono

Yoshikazu Uto

Tsuyoshi Homma

Kiyoshi Oizumi

Takeshi Shiiki

Juri Yoshida

Koji Matsumoto

Takayuki Baba

Kazuki Yano

Katsuhiro Kawakami

Toshiaki Nakahira

Satoru Naito

Daigo Asano

Takashi Yanagimoto

Takeshi Shida

Atsushi Tengeiji

Toshihiro Kiho

Yoshihiko Shimura

Masatoshi Honzumi

Iwamoto,osamu

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R: e.g., a C1-C6 alkyl group; R: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R: e.g., a C1-C6 alkyl group.

Griseofulvin compound

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below:R: e.g., a C1-C6 alkyl group; R: a C1-C6 alkyl group;A: e.g., an oxygen atom; and R: e.g., a C1-C6 alkyl group.

It is an object of the present invention to provide a medicament for preventing or treating hyperphosphatemia. Solution: A compound represented by a general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, R: a methyl group or the like, R: a hydrogen atom or the like, R: a hydrogen atom or the like, A: a cyclohexyl ring or the like, X: CH or the like, Y: CH or the like, Z: CH or the like, and n: 2 or the like).

Dicarboxylic acid compound

It is an object of the present invention to provide a medicament for preventing or treating hyperphosphatemia. Solution: A compound represented by a general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, R: a methyl group or the like, R: a hydrogen atom or the like, R: a hydrogen atom or the like, A: a cyclohexyl ring or the like, X: CH or the like, Y: CH or the like, Z: CH or the like, and n: 2 or the like].

Compounds or pharmacologically acceptable salts thereof for promoting osteogenesis, improving bone metabolism, preventing or treating bone fracture, preventing or treating a disease associated with bone metabolism, or in the field of orthopedics for the promotion of healing of bone fracture, a bone defect, and bone diseases such as osteoarthritis as well as in the field of dentistry for the treatment of periodontal disease and the stabilization of artificial tooth root. The compounds are represented by formula (I) or a pharmacologically acceptable salt thereof: 

Chromone derivative having osteogenesis promoting effect

[Object] A prophylactic or therapeutic agent for a cardiovascular disease is provided. [Means for Resolution] An atropisomer of a compound represented by the following general formula (I): (wherein Ris a C1-C3 alkyl group or a hydroxy-C1-C3 alkyl group; and Ris a hydrogen atom or a C1-C3 alkoxy group).

Atropisomer of pyrrole derivative

Compounds exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof: 

Cyclic compound having hetero atom

The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases, nephropathy, fibrosis, primary aldosteronism or edema. The compound is of the following general formula (I): wherein Rrepresents a C1-C3 alkyl group; Rrepresents a hydroxy-C1-C4 alkyl group and the like; Rrepresents a halogeno group, a halogeno-C1-C3 alkyl group and the like; Rrepresents a hydrogen atom, a halogeno group and the like, &#x2014;Rrepresents a sulfamoyl group or a C1-C3 alkylsulfonyl group; Rrepresents a hydrogen atom, a halogeno group and the like] or an N-oxide, atropisomer of the foregoing, or pharmaceutically acceptable salt of the foregoing. 

1-phenylpyrrole derivatives

A printed wiring board includes a bridge located in a surface layer, a noise absorber located on the bridge, a plurality of grounds directly connected or high-frequency-connected to the bridge, a first device using one of the plurality of grounds as a reference potential, a second device using one of the plurality of grounds other than the ground for the first device as a reference potential, and a high-speed signal line that connects the first device and the second device. The high-speed signal line is routed through a layer adjacent to the bridge in a layer direction of the printed wiring board to form a transmission line structure.

Printed wiring board

A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein,

Substituted acrylamide derivative and pharmaceutical composition comprising the same

Growing community of inventors

Tokyo, Japan

Kazumasa Aoki